Oryzon Genomics SA - Asset Resilience Ratio
Oryzon Genomics SA (ORY) has an Asset Resilience Ratio of 0.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Oryzon Genomics SA's Asset Resilience Ratio has changed over time. Check ORY PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Oryzon Genomics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Oryzon Genomics SA market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €14.58K | 0.01% |
| Total Liquid Assets | €14.58K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Oryzon Genomics SA maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Oryzon Genomics SA Industry Peers by Asset Resilience Ratio
Compare Oryzon Genomics SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896 |
Biotechnology | 12.69% |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399 |
Biotechnology | 37.23% |
Annual Asset Resilience Ratio for Oryzon Genomics SA (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Oryzon Genomics SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | €14.58K ≈ $17.05K |
€144.52 Million ≈ $168.96 Million |
-- |
| 2020-12-31 | 0.00% | €0.00 ≈ $0.00 |
€94.11 Million ≈ $110.02 Million |
-- |
| 2019-12-31 | 0.18% | €141.56K ≈ $165.49K |
€80.09 Million ≈ $93.64 Million |
-0.03pp |
| 2018-12-31 | 0.21% | €141.56K ≈ $165.49K |
€67.45 Million ≈ $78.86 Million |
-0.14pp |
| 2017-12-31 | 0.35% | €213.18K ≈ $249.23K |
€61.04 Million ≈ $71.37 Million |
-10.19pp |
| 2016-12-31 | 10.54% | €5.24 Million ≈ $6.13 Million |
€49.74 Million ≈ $58.16 Million |
+4.99pp |
| 2015-12-31 | 5.55% | €2.26 Million ≈ $2.64 Million |
€40.73 Million ≈ $47.62 Million |
-16.10pp |
| 2014-12-31 | 21.65% | €5.64 Million ≈ $6.60 Million |
€26.06 Million ≈ $30.46 Million |
+21.16pp |
| 2013-12-31 | 0.49% | €142.00K ≈ $166.01K |
€28.76 Million ≈ $33.63 Million |
-1.26pp |
| 2012-12-31 | 1.76% | €506.00K ≈ $591.57K |
€28.78 Million ≈ $33.65 Million |
-6.15pp |
| 2011-12-31 | 7.91% | €2.31 Million ≈ $2.70 Million |
€29.21 Million ≈ $34.15 Million |
-- |
About Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-… Read more